secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001867096-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance
----------------------------------------------------------------------

- Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.
- Q4 Recorlev net revenue $45M; full-year Recorlev net revenue $139M.
- Gvoke revenue grew >13% YoY; Keveyis patient base expanded vs. year-end 2024.
- Positive Adjusted EBITDA delivered in each quarter of 2025.
- Full 2025 results and 2026 outlook to be released March 2, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/0001867096-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/xers-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer